<DOC>
	<DOCNO>NCT02605356</DOCNO>
	<brief_summary>This study conduct 2 part . The phase 1b part international , phase 1b , open-label , dose-escalation assessment radium-223 dichloride administer bortezomib dexamethasone subject relapse multiple myeloma . The primary endpoint phase 1b part determine optimal dose radium-223 dichloride combination bortezomib/dexamethasone Phase 2 portion study . The phase 2 part international , phase 2 , double-blind , randomize , placebo-controlled assessment radium-223 dichloride versus placebo administer bortezomib dexamethasone , subject relapse multiple myeloma . Randomization ( 1:1 ) phase 2 part stratify : - Prior bortezomib treatment ( yes , ) - Prior treatment ( 1 prior line treatment , &gt; 1 prior line treatment ) Approximately 30 subject ( 10 subject per cohort ) enrol phase 1b part study approximately 196 subject enrol phase 2 part study .</brief_summary>
	<brief_title>Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Cytologically histologically confirm diagnosis multiple myeloma Subjects must receive least 1 3 previous line treatment response treatment ( i.e. , achieve minimal response [ MR ] better ) accord International Myeloma Working Group ( IMWG ) uniform response criterion Subjects must progressive disease accord IMWG uniform response criterion follow last multiple myeloma treatment Subjects must measurable disease define least 1 follow ( accord central laboratory result ) : Serum Mprotein ≥1 g/dL Urine Mprotein ≥200 mg/24 hour Serum free light chain ( FLC ) ≥10 mg/dL abnormal ratio ≥1 bone lesion identifiable radiograph , compute tomography , magnetic resonance imaging , bone scintigraphy Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 Subjects must nonrefractory bortezomib progression within 60 day completion bortezomib Absolute neutrophil count ( ANC ) ≥1.5 × 10e9/L , hemoglobin ( Hb ) ≥9.0 g/dL , platelet count ≥75.0 × 10e9/L independent transfusion red blood cell ( RBC ) platelet concentrate independent granulocyte colony stimulate factor ( GCSF ) granulocyte macrophage colony stimulate factor ( GMCSF ) Systemic glucocorticoid therapy ( prednisone &gt; 10 mg/day orally equivalent ) within last 4 week prior first dose , unless taper stable dose ≤10 mg/day least 1 week Subjects know POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) light chain ( AL ) amyloidosis Plasma cell leukemia Systemic anticancer therapy within 4 week prior first dose Radiation therapy previous 4 week prior first dose except give pain management involve less 10 % bone marrow Prior treatment radium223 dichloride experimental radiopharmaceutical Congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) , symptomatic cardiac ischemia , cardiomyopathy , clinically relevant ventricular arrhythmia , pericardial disease , unstable angina myocardial infarct previous 6 month prior first dose , leave ventricular ejection fraction &lt; 40 % Neuropathy ≥ Grade 2 Grade 1 pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Radium-223 dichloride</keyword>
	<keyword>bortezomib</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>early relapse multiple myeloma</keyword>
	<keyword>combination therapy multiple myeloma</keyword>
</DOC>